Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Trial Profile

Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Bendamustine (Primary) ; Dexamethasone (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2021.
    • 14 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2017.
    • 06 Dec 2016 Results of final analysis (n=31) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top